Breaking News
Sort by:
Top Post
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases […]
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today the filing with the […]
Roche Receives FDA Approval for VENTANA MMR RxDx Panel to Identify dMMR Solid Tumour Patients and pMMR Endometrial Cancer Patients Eligible for KEYTRUDA
Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of a […]
ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy
ELIAS Animal Health recently presented new mechanism of action data for the ELIAS Cancer Immunotherapy (ECI®) […]
GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
GentiBio, Inc., an engineered regulatory T cells (Tregs) company, announced today that it has entered […]
Mersana Therapeutics Announces Substantial Co-Development and Commercialization Collaboration for an ImmunoADC Targeting HER2 Cancers with GSK
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a […]
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors
Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces the completion of first patient dosing in […]
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to […]
Gilead Sciences to Acquire MiroBio
Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring […]
Immunologix Laboratories Appoints Dr. Corinna Fiorotti As Chief Commercial Officer (CCO)
Immunologix Laboratories announced today that Dr. Corinna Fiorotti has been appointed Chief Commercial Officer. An experienced science and business […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more